| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 05/11/2005 | EP1529062A2 Diagnostic and therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signaltransduction |
| 05/11/2005 | EP1529047A2 New purine derivatives |
| 05/11/2005 | EP1529046A1 Substituted benzimidazole compounds |
| 05/11/2005 | EP1529043A1 Novel process |
| 05/11/2005 | EP1529031A1 Acylated arylcycloalkylamines and their use as pharmaceuticals |
| 05/11/2005 | EP1528931A1 Methods for improving islet signaling in diabetes mellitus and for its prevention |
| 05/11/2005 | EP1528924A1 Mch1r antagonists |
| 05/11/2005 | EP1528923A1 N-((3-oxo-2,3-dihydro-1h-isoindol-1-yl)acetyl)guanidine derivatives as nhe1-inhibitors for the treatment of infarction and angina pectoris |
| 05/11/2005 | EP1487967A4 Chimeric pancreas |
| 05/11/2005 | EP1397363B1 5-ethyl-imidazotriazinones |
| 05/11/2005 | EP1309563B1 Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases |
| 05/11/2005 | EP1257526B1 Aniline-derived ligands for the thyroid receptor |
| 05/11/2005 | EP1254138B1 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase |
| 05/11/2005 | EP1100771B1 Compounds and compositions for delivering active agents |
| 05/11/2005 | EP1076563B1 Dipeptide caspase inhibitors and the use thereof |
| 05/11/2005 | CN1615357A Process for the manufacture of human mononuclear phagocytic leukocytes |
| 05/11/2005 | CN1615309A Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors |
| 05/11/2005 | CN1615307A Process and intermediates for pyridazinone antidiabetic agents |
| 05/11/2005 | CN1615305A Coumarin derivatives, process for their production and use thereof |
| 05/11/2005 | CN1615299A Xanthine oxidase inhibitors |
| 05/11/2005 | CN1615295A Compounds for treatment of inflammation, diabetes and related disorders |
| 05/11/2005 | CN1615150A Assay for the detection of factors that modulate the expression of INGAP |
| 05/11/2005 | CN1615148A Methods and compositions for derepression of IAP-inhibited caspase |
| 05/11/2005 | CN1615146A 生姜提取物制剂 Ginger extract preparation |
| 05/11/2005 | CN1615140A Polynucleotide therapy |
| 05/11/2005 | CN1615139A 25-hydroxy vitamin D3 compositions |
| 05/11/2005 | CN1615134A Pharmaceutical compositions comprising valsartan and NEP inhibitors |
| 05/11/2005 | CN1614028A Dried bacterial powder process containing gamma-linolenic acid |
| 05/11/2005 | CN1613488A Bitter bamboo leaf capsule, preparation and use thereof |
| 05/11/2005 | CN1613478A Chinese medicine composition for lowering blood fat and reducing weight and preparation thereof |
| 05/11/2005 | CN1613455A Targeting microorgan micro-capsules and their preparation |
| 05/11/2005 | CN1613449A Injections containing Fuliconzone and their preparation |
| 05/11/2005 | CN1201003C Adipocyte-specific protein homologs |
| 05/11/2005 | CN1200949C Covalently bridged insulin dimers |
| 05/11/2005 | CN1200939C Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same |
| 05/11/2005 | CN1200719C Health food capable of regulating blood lipoid and delaying senility |
| 05/11/2005 | CN1200699C Anthracyclinone derivatives and their use in amyloidosis |
| 05/10/2005 | US6891082 Transgenic nonhuman animal whose genome contains a nucleic acid sequence comprising a truncated Activin Type II receptor gene and a muscle-specific promoter operably linked and integrated into genome of animal; increased muscle mass |
| 05/10/2005 | US6891062 Pharmaceutical composition for treatment of diseases associated with decrease in bone mass |
| 05/10/2005 | US6891054 Functional acylglycerides |
| 05/10/2005 | US6891047 Process for the preparation of amorphous atorvastatin |
| 05/10/2005 | US6890958 Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications |
| 05/10/2005 | US6890957 Liquid formulation of metformin |
| 05/10/2005 | US6890949 Amino ceramide-like compounds and therapeutic methods of use |
| 05/10/2005 | US6890947 (S)-3-(1-(2-(2-chloro-phenyl)-5-methyl-oxazol-4-ylmethyl)-1H -indol-5-yl)-2-ethoxy-propionic acid; peroxisome proliferator activated receptors (PPARs) |
| 05/10/2005 | US6890943 3-acylated pyridoxal derivatives used to treat vitamin B6 deficiency, cardiovascular diseases, melanoma and other related diseases |
| 05/10/2005 | US6890929 Immunosuppressants; lupus, multiple sclerosis, skin disorders, antiarthritic agents, antihistamines, antiulcer agents, Crohn's disease |
| 05/10/2005 | US6890927 Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| 05/10/2005 | US6890925 Treating insulin resistance, hypertension, angina, ischemia, renal disease or Raynaud's disease, by administering pyrazole derivatives such as 1-(p-(morpholinocarbonylamino)phenyl)-3,5-di(trifluoromethyl)pyrazole |
| 05/10/2005 | US6890915 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| 05/10/2005 | US6890914 Method of locking 1α-OH of vitamin D compounds in axial orientation |
| 05/10/2005 | US6890899 A lipolytic or lipid mobilising factor (LMF) produced by the cachexia-inducing murine tumor MAC16; weight reduction or controlling obesity; administering a Zn-alpha 2-glycoprotein |
| 05/10/2005 | US6890550 Method of preventing parturient hypocalcemia in animals and compositions used therein |
| 05/10/2005 | US6890549 Reducing levels of bioavailable fat by adminstering alpha-cyclodextrin |
| 05/10/2005 | US6890518 Compositions of chemically modified insulin |
| 05/10/2005 | US6890457 Infrared radiation emitting ceramic powders comprising zirconium or radium and oxides of silicon, aluminum, iron, titanium, calcium, magnesium, potassium and sodium, used for joining wood, paper, leather, metals or plastics; radiotherapy |
| 05/10/2005 | CA2407562C Tryptophan source from plants and uses therefor |
| 05/10/2005 | CA2363451C Oilseed processing |
| 05/10/2005 | CA2116559C Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
| 05/06/2005 | WO2005040148A1 New rar$g(b) receptor-activating ligand, method for the preparation thereof and use thereof in human medicine and in cosmetics |
| 05/06/2005 | WO2005039602A1 Pharmacologically functional water and use thereof |
| 05/06/2005 | WO2005039559A1 Composition functioning to prevent or mitigate symptom or disease attributable to blood vessel aging |
| 05/06/2005 | WO2005039541A1 Coenzyme q10 enclosing capsule |
| 05/06/2005 | WO2005021541A3 Process for the production of polymorphs of rosiglitazone maleate |
| 05/06/2005 | WO2004032967A8 Association between a ppar ligand and an antioxidant agent and use thereof for treating obesity |
| 05/06/2005 | WO2003068146A3 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
| 05/06/2005 | WO2003018606A3 Casein derived peptides and uses thereof in therapy |
| 05/06/2005 | WO2003010286A3 Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 05/06/2005 | CA2544099A1 Peptides with anti-obesity activity and other related uses |
| 05/06/2005 | CA2544086A1 Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof |
| 05/06/2005 | CA2543498A1 Use of hydroxylated amino acids for treating diabetes |
| 05/06/2005 | CA2543404A1 Novel inhibitor of the formation of advanced glycation end product and aldose reductase inhibitor |
| 05/06/2005 | CA2543342A1 Combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity and lipase inhibitors |
| 05/06/2005 | CA2542172A1 Therapeutic applications for c-peptide |
| 05/06/2005 | CA2541894A1 Amino alcohol derivative, medicinal composition containing the same, and use of these |
| 05/06/2005 | CA2539726A1 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase |
| 05/06/2005 | CA2539193A1 New rarbeta receptor-activating ligand, method for the preparation ther eof and use thereof in human medicine and in cosmetics |
| 05/05/2005 | US20050096632 Intradermal delivery of substances |
| 05/05/2005 | US20050096631 Intradermal delivery of substances |
| 05/05/2005 | US20050096630 Intradermal delivery of substances |
| 05/05/2005 | US20050096479 Novel succinate salt of O-desmethyl-venlafaxine |
| 05/05/2005 | US20050096468 Inhibitors of histone deacetylase |
| 05/05/2005 | US20050096392 Use of creatine pyruvate for increasing stamina during highly intensive intermittent physical exertion |
| 05/05/2005 | US20050096377 Substituted sulfonamide-indoles |
| 05/05/2005 | US20050096363 Activator of peroxisome proliferator-activated receptor delta |
| 05/05/2005 | US20050096359 melanocortin receptor agonist, antagonist; preventing or treating inflammatory diseases, AIDS, obesity, bulimia, anorexia or sexual dysfunction; N-(2-aminoethyl)-3'-[1-{N-(1-benzylpiperidin-4-yl)-N-(2-naphthylacetyl)aminoethyl][1,1'-biphenyl)-2-carboxamide dihydrochloride |
| 05/05/2005 | US20050096348 non-insulin dependent diabetes mellitus, and impaired glucose tolerance; dipeptidyl peptidase IV (DPP-IV) inhibitors eg (2S)-1-{[(1S)-2-(5-cyano-2-methyl-indol-1-yl)-1-methyl-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile |
| 05/05/2005 | US20050096347 Beta3-Adrenoreceptor agonists, agonist compositions and methods of using |
| 05/05/2005 | US20050096335 Heteroaryl - fused nitrogen heterocycles as therapeutic agents |
| 05/05/2005 | US20050096334 Use of substance P antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of NK-1 receptor antagonists for the treatment of chronic fatigue syndrome |
| 05/05/2005 | US20050096331 Alkyl carboxylic acids and their derivatives; antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds; better efficacy, potency and lower toxicity |
| 05/05/2005 | US20050096330 N-(indolecarbonyl) piperazine derivatives |
| 05/05/2005 | US20050096326 4-(4-methylpiperazin-1-yl)4V-(4-morpholinophenyl)-indan-2-carboxamide; h5-HT1B receptor antagonist; serotonin-mediated disorders; oral bioavailability |
| 05/05/2005 | US20050096321 affinity for peripheral-type benzodiazepine receptors; in vitro and in vivo affinity; chemical intermediates |
| 05/05/2005 | US20050096316 Quinoline derivatives(2) |
| 05/05/2005 | US20050096313 Substance P; 2-(phenyl)-4-(3-oxo-piperazin-1-yl-)-piperidine-1-carboxylic acid; benzyl-methylamide; antagonists of the NK1 receptor; antidepressant, antiolytic; antiemetic |
| 05/05/2005 | US20050096312 Antiserotonine agents; antidepressants; eating disorders; anxiolytic agents; sleep disorders; gastrointestinal disorders; cardiovascular disorders; muscular disorders; endocrine system diseases; muscular disorders; psychological disorders |
| 05/05/2005 | US20050096279 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| 05/05/2005 | US20050096266 Administering trypsin inhibitor and amino acid |
| 05/05/2005 | US20050095710 Antisense modulation of PTP1B expression |